ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma
Proceedings of the National Academy of Sciences, 2001•National Acad Sciences
DPC4 is known to mediate signals initiated by type β transforming growth factor (TGFβ) as
well as by other TGFβ superfamily ligands such as activin and BMP (bone morphogenic
proteins), but mutational surveys of such non-TGFβ receptors have been negative to date.
Here we describe the gene structure and novel somatic mutations of the activin type I
receptor, ACVR1B, in pancreatic cancer. ACVR1B has not been described previously as a
mutated tumor-suppressor gene.
well as by other TGFβ superfamily ligands such as activin and BMP (bone morphogenic
proteins), but mutational surveys of such non-TGFβ receptors have been negative to date.
Here we describe the gene structure and novel somatic mutations of the activin type I
receptor, ACVR1B, in pancreatic cancer. ACVR1B has not been described previously as a
mutated tumor-suppressor gene.
DPC4 is known to mediate signals initiated by type β transforming growth factor (TGFβ) as well as by other TGFβ superfamily ligands such as activin and BMP (bone morphogenic proteins), but mutational surveys of such non-TGFβ receptors have been negative to date. Here we describe the gene structure and novel somatic mutations of the activin type I receptor, ACVR1B, in pancreatic cancer. ACVR1B has not been described previously as a mutated tumor-suppressor gene.
National Acad Sciences